AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
30 Outubro 2023 - 9:55AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM”), an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders, and viral diseases, including COVID-19,
the disease caused by the SARS-CoV-2 virus, today announced that an
abstract from the Magee-Womens Research Institute at the University
of Pittsburgh School of Medicine (“UPMC") has been accepted for
poster presentation at the Society for Immunotherapy of Cancer
(SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San
Diego, CA and virtually.
The abstract concerns a Phase 2 single arm
efficacy/safety trial to evaluate the effectiveness of combining
intensive locoregional intraperitoneal (IP) chemoimmunotherapy of
cisplatin with AIM’s drug Ampligen and IV infusion of the
checkpoint inhibitor pembrolizumab for patients with recurrent
platinum-sensitive ovarian cancer. The abstract authors include
Robert Edwards, MD, Chief Medical Officer of the UPMC Community and
Ambulatory Services Division and Co-Director of the Women’s Cancer
Research Center at the UPMC Hillman Cancer Center.
Details for the presentation are as follows:
Abstract Number: 799 Title: Combination
intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic
locoregional response in patients with recurrent platinum-sensitive
ovarian cancer
For more information, please visit the SITC
website.
About AIM ImmunoTech Inc.AIM
ImmunoTech Inc. is an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders and viral diseases, including COVID-19. The
company’s lead product is a first-in-class investigational drug
called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3
agonist immuno-modulator with broad spectrum activity in clinical
trials for globally important cancers, viral diseases and disorders
of the immune system.For more information, please
visit aimimmuno.com and connect with the company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024